InflaRx (IFRX)

• Market cap: $144M
• 1 day: 9.37%
• 5 days: 6.06%
• 1 month: 15.57%
• 3 months: 65.54%
• 6 months: 46.71%
• Year to date: 49.39%
• 1 year: 44.97%
• 5 years: -38.75%
• 10 years: -83.66%

About: InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Employees: 66

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

1.98% less ownership

Funds ownership: 23.83% [Q2] → 21.85% (-1.98%) [Q3]

18% less funds holding

Funds holding: 33 [Q2] → 27 (-6) [Q3]

19% less capital invested

Capital invested by funds: $24.4M [Q2] → $19.7M (-$4.73M) [Q3]

50% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 8

60% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 10

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $8 227% upside
• Avg. target: $8 227% upside
• High target: $8 227% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Edward White 23% 1-year accuracy 32 / 139 met price target

227% upside $8

Buy Reiterated

20 Dec 2024